A Value Based Program to Reduce Major Adverse Cardiac Events (MACE)

For this webinar, we centered our discussion around Value Based Programs that reduce major adverse cardiac events (MACE) with Semler Scientific.

Recently released data from the World Health Organization confirms that ischemic heart disease and stroke remain the leading causes of morbidity and mortality. The results are worse over the last 20 years.

The American Heart Association data confirms that the US statistics are even worse, with a death rate of 217 per one hundred thousand. This translates to a cardiovascular related death every 36 seconds and a stroke death every 3 ½ minutes. There are a range of contributing factors, but the inability to detect early stage disease is key.

This webinar taught:
1. How early Peripheral Arterial Disease (PAD) recognition can lead to reductions in Cardiovascular Morbidity & Mortality
2. Why prior efforts have been inconclusive in improving outcomes
3. How QuantaFlo works & can add value in primary care
4. Relationship between a positive QuantaFlo test and all cause mortality/MACE

Featured speaker:
Jay Long, MD, is a retired Vascular Surgeon, who was involved in early work on validating Semler Scientific’s QuantaFlo system to detect peripheral arterial disease. He now serves as the Medical Director for Semler Scientific.